 Dear Reader, Five years from now, there will be two kinds of investors... The ones who built generational wealth in the right stocks. And the ones who stayed in the wrong ones. I've spent nearly two decades running a hedge fund firm in Manhattan. I recommended Netflix before it soared 11,000%... Amazon before it gained 9,000%... Apple before it climbed 80,000%. CNBC called me "The Prophet" after I publicly predicted the Global Financial Crisis before almost anyone else saw it coming. >>> See my next prediction But I want to be direct with you today. Because what I'm watching unfold in America right now – a collision of the AI boom, the energy crisis, and the biggest commodity supercycle in 100 years – is unlike anything I've seen in my career. And one little-known company sits right at the center of all three. It controls critical assets so scarce and so strategically vital, the White House invoked emergency powers to protect them. One of the most decorated fund managers of the past 50 years put HALF his $9 billion into it. Google's former CEO just partnered with it. And I believe a $10,000 investment in this company today could grow to $220,000 over the long term. I've recorded a free presentation. The full name, ticker, and complete story. The window won't be open forever. >>> Watch My Free Presentation: America's Greatest Retirement Stock Right Now I didn't just read about it. I flew to West Texas with one of our most trusted boots-on-the-ground sources... A man who called the largest oilfield in American history before Wall Street even knew the name. 
We took a helicopter over the Stargate construction site together... What I saw below us removed any doubt. 
Regards, Whitney Tilson
Senior Analyst, Stansberry Research P.S. Here's what I think happens in mid-July Trump signed "Project Vault" on January 14th. His team had 180 days to go make deals to secure America's supply of these minerals. Mid-July is the check-in. If the deals got done — great. If they didn't — he has already put certain options on the table. Price floors. Tariffs. Government rules protecting these exact minerals. Now think about what that means for this stock. It controls the very assets Washington is now fighting over — sitting at a rare discount. And if price floors go in... the floor goes in UNDER your position. That's a very different situation than buying after everyone figures that out. Five years from now, there will be two kinds of investors. The ones who were in before mid-July... And the ones who watched. >>> Watch the free presentation before the deadline hits. <<<
Additional Reading from MarketBeat.com
3 Overlooked Stocks Positioned for the Next Market RotationBy Bridget Bennett. Date Posted: 7/13/2026. 
Key Points
- Oxford Club strategist Marc Lichtenfeld argues investors should diversify beyond technology as healthcare, insurance and regional banking sectors quietly build momentum in 2026.
- Ligand Pharmaceuticals licenses out early-stage drug rights instead of funding trials itself, with management projecting earnings to triple by 2030 and quadruple by 2032.
- Aflac and Atlantic Union Bankshares benefit from elevated interest rates and offer long dividend growth streaks, positioning them as steady compounders rather than fast-moving trades.
- Special Report: Sell these "safe" blue chips immediately
Tech has carried this market for years, but it isn't the only game in town anymore. Small caps are outperforming in 2026, the Magnificent Seven have cooled, and money is starting to flow into corners of the market that retail investors rarely check. Healthcare, insurance, and regional banking are all quietly building momentum before the crowd shows up. That's the setup Oxford Club Chief Income Strategist Marc Lichtenfeld is watching right now. His view is that the sectors working today won't stay secret for long, and getting positioned early, before the next rotation becomes obvious, is where the real edge lies. Why Diversification Still Matters in a One-Sector Market
Concentration feels good on the way up. Artificial intelligence stocks have proven that this year, and it's tempting to let one winning trade become the bulk of a portfolio. The problem shows up on the way down. Stocks take the stairs up, but the elevator down—and a sector that's been running hot for a while tends to fall hard and fast when it finally turns. Investors who got used to buying every dip often get caught waiting for a bounce that doesn't materialize as quickly as they expect. That's the trap concentration sets. It works until it doesn't, and by then it's often too late to rotate out cleanly. Lichtenfeld's point isn't to abandon technology. It's to make sure a portfolio has other legs to stand on when one leg gets wobbly, including sectors that are already working quietly and that most retail investors haven't circled back to yet. Ligand Pharmaceuticals Turns Drug Risk Into Someone Else's ProblemHealthcare tends to hold up in any economy, recession or not, because people don't stop needing medicine. Within that sector, Ligand Pharmaceuticals (NASDAQ: LGND) stands out for a business model that looks more like a royalty company than a traditional biotech. Instead of spending years and billions to push a single drug through trials, a process that can take eight to 10 years, Ligand acquires early-stage drug rights and licenses them out. The company that licenses the drug absorbs the development risk and cost. Ligand collects the royalty. The market is pricing in serious growth. Management expects earnings to triple by 2030 and quadruple by 2032, backed by more than 100 drugs already commercialized or in development and a lean 80-person team. The company has been cash-flow positive in nine of the past 10 years, with roughly $780 million in cash on hand. Shares have already run hard, which is part of why analyst price targets are lagging the stock. Lichtenfeld argues that's typical: Wall Street tends to raise targets after a move happens, not before. Short interest sitting near 9% of the float adds another wrinkle. If the stock keeps climbing, short sellers under pressure could eventually be forced to cover, adding fuel to the move. What could change sentiment is a licensing deal that disappoints or a slowdown in royalty growth. What to watch is whether earnings keep pace with those tripling and quadrupling projections. Aflac Is a Rate Play Hiding Inside an Insurance StockInsurance doesn't generate headlines like biotech, but the setup is compelling when interest rates stay elevated. Insurers invest customer premiums in conservative, interest-bearing assets, so higher rates widen the margin between what they collect and what they pay out. Aflac Incorporated (NYSE: AFL) fits that setup and adds a dividend track record—44 straight years of increases—plus a strong Japan business and a growing pet insurance line, a global market some projections show doubling to $17.5 billion by 2030. A notably low debt-to-equity ratio compared with peers gives the company room to expand if opportunities arise. Wall Street is skeptical here, too. Only four of 13 analysts rate the stock a Buy, which Lichtenfeld frames as upside if sentiment shifts rather than a warning sign. Earnings are projected to grow 20% between 2026 and 2029, a steadier and less dramatic path than Ligand's. What could change the story is a sustained drop in interest rates, which would compress that investment margin. What to watch is continued dividend growth alongside the Japan and pet insurance segments. Atlantic Union Bankshares Offers Slow, Steady CompoundingRegional banks benefit from the same rate dynamic as insurers, and Atlantic Union Bankshares (NYSE: AUB) is a name most investors outside the Mid-Atlantic have likely never heard of. The Virginia-based bank has operated for 124 years under just five CEOs, a continuity that shows up in the numbers. Its cost of deposits runs about 20 basis points below the national average, non-performing loans sit at a low 0.36% of the portfolio, and net charge-offs are close to zero at 0.02%. Management expects tangible book value, a common way to value banks, to grow 12% to 15% this year. The dividend yield is roughly 3.5%, with annual increases over the past 15 years and a recent raise of nearly 10%. This isn't a stock built for a quick double. It's built to compound. What could change sentiment is a spike in loan losses or a sharp move lower in rates. What to watch is whether tangible book value growth holds near that double-digit target. Where the Real Money Gets MadeNone of these three will move like an AI trade, and that's the point. Ligand offers biotech-style growth without full biotech risk. Aflac and Atlantic Union offer the kind of grinding, dividend-fueled compounding that builds real wealth over a decade, not a quarter. Stay diversified, because that's what keeps a portfolio standing when the hot sector eventually cools.
This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here.
. |
